Table 1.
Baseline characteristics of patients who received warfarin or a NOAC for AF.
| All Warfarin (n = 2,659) | All NOAC (n = 3,733) | Reduced Dose of a NOAC (n = 1,554)† | Standard Dose of a NOAC (n = 2,179)‡ | |||
|---|---|---|---|---|---|---|
| On-label (n = 777) | Off-label (n = 733) | On-label (n = 1,873) | Off-label (n = 226) | |||
| Age, years | 65.3 ± 11.9 | 68.0 ± 11.4* | 77.3 ± 8.1* | 70.9 ± 8.2*,** | 62.4 ± 10.7* | 73.0 ± 9.2* |
| Female | 820 (30.8) | 1,404 (37.6)* | 474 (61.0)* | 273 (37.2)*,** | 496 (26.5)* | 114 (50.4)* |
| Height, cm | 164.3 ± 9.4 | 163.4 ± 9.5* | 156.5 ± 8.8* | 163.1 ± 8.1*,** | 166.9 ± 8.6* | 159.4 ± 8.8* |
| Weight, kg | 67.7 ± 12.1 | 66.6 ± 12.0* | 56.8 ± 9.7* | 67.7 ± 10.2** | 71.0 ± 11.2* | 59.3 ± 8.5* |
| HTN | 1,980 (74.5) | 2,837 (76.0) | 650 (83.7)* | 626 (85.4)*,** | 1,315 (70.2)* | 176 (77.9) |
| DM | 717 (27.0) | 1,015 (27.2) | 239 (30.8) | 241 (32.9)*,** | 452 (24.1)* | 70 (31.0) |
| CHF | 865 (32.5) | 862 (23.1)* | 303 (39.0)* | 202 (27.6)*,** | 282 (15.1)* | 68 (30.1) |
| Any prior TE§ | 600 (22.6) | 1,029 (27.6)* | 311 (40.0)* | 218 (29.7)*,** | 414 (22.1) | 82 (36.3)* |
| CHA2DS2-VASc score¶ | 3 (1, 4) | 3 (2, 4)* | 4 (3, 6)* | 3 (2, 5)*,** | 2 (1, 3)* | 4 (3, 5)* |
| Concomitant AP | 296 (11.1) | 234 (6.3)* | 70 (9.0) | 84 (11.5)** | 65 (3.5)* | 15 (6.6)* |
| sCCr, mL/min | 68.6 ± 27.2 | 66.6 ± 24.7* | 43.9 ± 14.7* | 64.5 ± 18.4*,** | 78.6 ± 23.0* | 51.2 ± 16.6* |
| LV EF, % | 51.6 ± 10.0 | 52.7 ± 8.7* | 51.9 ± 10.0 | 52.4 ± 8.9 | 53.2 ± 7.9* | 51.9 ± 9.8 |
| LAD | 44.6 ± 7.1 | 44.0 ± 7.0* | 44.7 ± 7.7 | 45.5 ± 7.3*,** | 43.2 ± 6.4* | 44.0 ± 7.3 |
| PDC, % | 92.0 ± 17.0 | 91.4 ± 19.1 | 91.9 ± 17.9 | 92.5 ± 17.4** | 90.8 ± 19.9* | 90.0 ± 23.3 |
| ≥80% | 2,152 (87.6) | 2,760 (86.6) | 595 (88.1) | 535 (88.6)** | 1,384 (85.1)* | 170 (86.3) |
Data are presented as the mean ±standard deviation, median (25th, 75th percentiles), or number (%).
*p < 0.05 with the all warfarin group.
**p < 0.05 between the off-label reduced dose and the on-label standard dose of NOAC groups.
†There were no label indication data for 44 patients.
‡There were no label indication data for 80 patients.
§Ischemic stroke, myocardial infarction, peripheral arterial disease, peripheral venous thromboembolism, and pulmonary embolism.
¶One point each for congestive heart failure, hypertension, age of 65–74 years, diabetes mellitus, and vascular disease (myocardial infarction or peripheral arterial disease), and two points for age of 75 years or older and a previous stroke.
Abbreviations: AP, antiplatelet drug; CHF, congestive heart failure; DM, diabetes mellitus; NOAC, non–vitamin K antagonist anticoagulant; HTN, hypertension; LAD, left atrial anteroposterior dimension; LV EF, left ventricular ejection fraction; MI, myocardial infarction; PDC, proportion of days covered; sCCr, serum creatinine clearance; TE, thromboembolism; TTR, time in therapeutic range.